SCARB1 and acute lymphoblastic leukemia: The ability of 92R (and Srb1) to inhibit infiltrates formation, is a relevant attribute of this Ab, related to its possible therapeutic use since, 30% to 70% of patients with advanced acute lymphoblastic leukemia before treatment develop infiltrates in the CNS (43).